Clinical trial
Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal…
NCT00445549 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00445549 |
|---|---|
| Title | Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
| Official title | Phase II Study of Clinical Activity and Proteomic Pathway Profiling of the Vascular Endothelial Growth Factor 2 (VEGFR2) Inhibitor, ZD6474 (Vandetanib) in Women With Relapsed or Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms |
| Intervention type | Drug |
| Interventions | Vandetanib |
| Enrollment | 12 |
| Start date | Jan 1, 2007 |
| Primary completion | Dec 1, 2008 |
| Completion | Oct 1, 2009 |
| First posted | Mar 9, 2007 |
| Last update posted | Jun 26, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: